Literature DB >> 34016832

Circular RNA circ_ASAP2 regulates drug sensitivity and functional behaviors of cisplatin-resistant gastric cancer cells by the miR-330-3p/NT5E axis.

Yongjun Sun1, Jie Ma, Junkai Lin, Dawei Sun, Ping Song, Lujing Shi, Hongtao Li, Ruijie Wang, Ziwen Wang, Shijun Liu.   

Abstract

This study aims to explore the biological actions of circular RNA (circRNA) ArfGAP with SH3 domain, ankyrin repeat and PH domain 2 (circ_ASAP2, circ_0006089) in cisplatin (DDP) resistance of gastric cancer. Circ_ASAP2, ecto-5'-nucleotidase (NT5E) and miR-330-3p were quantified by quantitative real-time PCR or western blot. The measurements of the IC50 value and cell proliferation were done using 3-[4,5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide (MTT) assay. Cell colony formation, cell cycle distribution, apoptosis, migration and invasion were evaluated by the colony formation, flow cytometry and transwell assays. Dual-luciferase reporter assay was performed to confirm the targeted relationship between different molecules. The role of circ_ASAP2 in tumor growth was gauged by in vivo animal studies. Circ_ASAP2 and NT5E were overexpressed in DDP-resistant gastric cancer tissues and cells. Knockdown of circ_ASAP2 promoted DDP sensitivity, apoptosis and repressed proliferation, migration and invasion of DDP-resistant gastric cancer cells in vitro and diminished tumor growth in vivo. Moreover, NT5E was a downstream effector of circ_ASAP2 in regulating cell DDP sensitivity and functional behaviors. Mechanistically, circ_ASAP2 directly bound to miR-330-3p to promote NT5E expression. Furthermore, circ_ASAP2 modulated cell DDP sensitivity and functional behaviors by targeting miR-330-3p. Knockdown of circ_ASAP2 promoted DDP sensitivity and suppressed malignant behaviors of DDP-resistant gastric cancer cells through targeting the miR-330-3p/NT5E axis.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34016832     DOI: 10.1097/CAD.0000000000001087

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  7 in total

1.  Clinical and radiological findings of glioblastomas harboring a BRAF V600E mutation.

Authors:  Yukitomo Ishi; Shigeru Yamaguchi; Michinari Okamoto; Ryosuke Sawaya; Shogo Endo; Hiroaki Motegi; Shunsuke Terasaka; Zen-Ichi Tanei; Kanako C Hatanaka; Shinya Tanaka; Miki Fujimura
Journal:  Brain Tumor Pathol       Date:  2022-04-01       Impact factor: 3.298

2.  The homeostatic malfunction of a novel feedback pathway formed by lncRNA021545, miR-330-3p and epiregulin contributes in hepatocarcinoma progression via mediating epithelial-mesenchymal transition.

Authors:  Siwen Yang; Yunkun Zhang; Chunmei Guo; Rui Liu; Maroua Elkharti; Zhenhua Ge; Qinlong Liu; Shuqing Liu; Ming-Zhong Sun
Journal:  Am J Cancer Res       Date:  2022-06-15       Impact factor: 5.942

3.  Circ ASAP2 decreased inflammation and ferroptosis in diabetic nephropathy through SOX2/SLC7A11 by miR-770-5p.

Authors:  Qin Li; Xiangjian Meng; Qiang Hua
Journal:  Acta Diabetol       Date:  2022-09-24       Impact factor: 4.087

Review 4.  Advances in the Study of CircRNAs in Tumor Drug Resistance.

Authors:  Song Wang; Long Qian; Tingting Cao; Li Xu; Yan Jin; Hao Hu; Qingsheng Fu; Qian Li; Ye Wang; Jiawei Wang; Yabin Xia; Xiaoxu Huang
Journal:  Front Oncol       Date:  2022-05-09       Impact factor: 5.738

Review 5.  The Role of Circular RNAs in the Drug Resistance of Cancers.

Authors:  Xin-Yuan Liu; Qi Zhang; Jing Guo; Peng Zhang; Hua Liu; Zi-Bin Tian; Cui-Ping Zhang; Xiao-Yu Li
Journal:  Front Oncol       Date:  2022-01-05       Impact factor: 6.244

Review 6.  The Emerging Roles of Circular RNAs in the Chemoresistance of Gastrointestinal Cancer.

Authors:  Man Wang; Fei Yu; Yuan Zhang; Lei Zhang; Wenguang Chang; Kun Wang
Journal:  Front Cell Dev Biol       Date:  2022-01-21

7.  circ_0006089 promotes gastric cancer growth, metastasis, glycolysis, and angiogenesis by regulating miR-361-3p/TGFB1.

Authors:  Ying Zhou; Qilin Zhang; Bingling Liao; Xiaofeng Qiu; Sheng Hu; Qihua Xu
Journal:  Cancer Sci       Date:  2022-04-24       Impact factor: 6.518

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.